diaDexus gets US patent for heart disease test:
This article was originally published in Clinica
Executive Summary
diaDexus has been issued with a US patent covering its blood test for a patient's susceptibility to atherosclerosis. The immunoassay-based test measures the levels of Lp-PLA2, a risk factor for coronary heart disease (see Clinica No 931, p 19). The Santa Clara, California company says that Lp-PLA2 is independent of other known risk factors, including low-density lipoprotein cholesterol and C-reactive protein. The patent was licensed from GlaxoSmithKline, which discovered that Lp-PLA2 was associated with atherosclerotic plaque.
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.